Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
FA Mensah, JP Blaize, LJ Bryan - OncoTargets and therapy, 2018 - Taylor & Francis
The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and
proliferation has made it an attractive target in cancer therapy. The development of small …
proliferation has made it an attractive target in cancer therapy. The development of small …
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
AF Herrera, A Goy, A Mehta… - American journal of …, 2020 - Wiley Online Library
Abstract This phase 1b/2, multicenter, open‐label study evaluated ibrutinib plus durvalumab
in relapsed/refractory follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL) …
in relapsed/refractory follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL) …
Recent landmark studies in follicular lymphoma
M Sorigue, JM Sancho - Blood Reviews, 2019 - Elsevier
Follicular lymphoma (FL) is the most common indolent lymphoma. Therapeutic advances in
the past decade have improved its prognosis, but some questions remain open, particularly …
the past decade have improved its prognosis, but some questions remain open, particularly …
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 …
R Pettengell, R Uddin, A Boumendil… - Bone Marrow …, 2021 - nature.com
We report the 12-year follow-up of the prospective randomized EBMT LYM1 trial to
determine whether the benefit of brief duration rituximab maintenance (RM) on progression …
determine whether the benefit of brief duration rituximab maintenance (RM) on progression …
Validation of a cyclic algorithm to proxy number of lines of systemic cancer therapy using administrative data
PURPOSE Researchers are automating the process for identifying the number of lines of
systemic cancer therapy received by patients. To date, algorithm development has involved …
systemic cancer therapy received by patients. To date, algorithm development has involved …
A matching-adjusted Indirect comparison of single-arm trials in patients with relapsed or refractory follicular lymphoma who received at least two prior systemic …
D Proudman, D Nellesen, D Gupta, D Adib, J Yang… - Advances in …, 2022 - Springer
Introduction Tazemetostat is an enhancer of zeste homolog 2 (EZH2) inhibitor
recommended for patients with relapsed/refractory (R/R) follicular lymphoma (FL) after …
recommended for patients with relapsed/refractory (R/R) follicular lymphoma (FL) after …
Treatment of high-risk follicular lymphoma
W Jurczak - HemaSphere, 2019 - journals.lww.com
The majority of follicular lymphoma (FL) patients diagnosed in 2018 will probably die with
the disease and not of the disease—in assessing new regimens, their increased clinical …
the disease and not of the disease—in assessing new regimens, their increased clinical …